Effects of Atorvastatin versus Fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

被引:118
作者
Frost, RJA [1 ]
Otto, C [1 ]
Geiss, HC [1 ]
Schwandt, P [1 ]
Parhofer, KG [1 ]
机构
[1] Univ Munich, Klinikum Grosshadern, Dept Internal Med 2, D-81377 Munich, Germany
关键词
D O I
10.1016/S0002-9149(00)01270-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic dyslipoproteinemia characterized by hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, and often elevated low-density lipoprotein (LDL) cholesterol with predominance of small, dense LDL is a strong risk factor for atherosclerosis. It is unclear whether fibrate or statin therapy is more effective in these patients. We compared atorvastatin (10 mg/day) with fenofibrate (200 mg/day), each for 6 weeks separated by a 6-week washout period in 13 patients (5 men and 8 women; mean age 60.0 +/- 6.8 years; body mass index 30.0 +/- 3.0 kg/m(2)) with type 2 diabetes mellitus (hemoglobin A(1c) 7.3 +/- 1.1%) and mixed hyperlipoproteinemia (LDL cholesterol 164.0 +/- 37.8 mg/dl, triglycerides 259.7 +/- 107 mg/dl, HDL cholesterol 48.7 +/- 11.0 mg/dl) using a randomized, crossover design. Lipid profiles, LDL subfraction distribution, fasting plasma viscosity, red cell aggregation, and fibrinogen concentrations were determined before and after each drug. Atorvastatin decreased all LDL subfractions (LDL cholesterol, -29%; p <0.01) including small, dense LDL. Fenofibrate predominantly decreased triglyceride concentrations (triglycerides, -39%; p <0.005) and induced a shift, in LDL subtype distribution from small, dense LDL (-31%) to intermediate-dense LDL (+36%). The concentration of small, dense LDL was comparable during therapy to both drugs (atorvastatin 62.8 +/- 19.5 mg/dl, fenofibrate 63.0 +/- 18.1 mg/dl). Both drugs induced an increase in HDL cholesterol (atorvastatin +10%, p <0.05; fenofibrate +11%, p = 0.06). In addition, fenofibrate decreased fibrinogen concentration (-15%, p <0.01) associated with a decrease in plasma viscosity by 3% (p <0.01) and improved red cell aggregation by 15% (p <0.05), whereas atorvastatin did not affect any hemorheologic parameter. We conclude that atorvastatin and fenofibrate con improve lipoprotein metabolism in type 2 diabetes. However, the medications affect different aspects of lipoprotein metabolism. (C) 2001 by Excerpta Medico, Inc.
引用
收藏
页码:44 / 48
页数:5
相关论文
共 22 条
[1]   Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs [J].
Burnett, JR ;
Wilcox, LJ ;
Telford, DE ;
Kleinstiver, SJ ;
Barrett, PHR ;
Newton, RS ;
Huff, MW .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (11) :2589-2600
[2]  
CHAPMAN MJ, 1981, J LIPID RES, V22, P339
[3]   BLOOD VISCOSITY - INFLUENCE OF ERYTHROCYTE AGGREGATION [J].
CHIEN, S ;
USAMI, S ;
DELLENBACK, RJ ;
GREGERSEN, MI ;
NANNINGA, LB ;
GUEST, MM .
SCIENCE, 1967, 157 (3790) :829-+
[4]   A multicenter, double-blind, one-year study comparing safety and efficacy of Atorvastatin versus Simvastatin in patients with hypercholesterolemia [J].
Dart, A ;
Jerums, G ;
Nicholson, G ;
dEmden, M ;
HamiltonCraig, I ;
Tallis, G ;
Best, J ;
West, M ;
Sullivan, D ;
Bracs, P ;
Black, D .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (01) :39-44
[5]   Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia [J].
de la Serna, G ;
Cadarso, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) :166-172
[6]   Action of atorvastatin in combined hyperlipidemia - Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles [J].
Guerin, M ;
Lassel, TS ;
Le Goff, W ;
Farnier, M ;
Chapman, MJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (01) :189-197
[7]   Triglyceride concentration and ischemic heart disease - An eight-year follow-up in the Copenhagen Male Study [J].
Jeppesen, J ;
Hein, HO ;
Suadicani, P ;
Gyntelberg, F .
CIRCULATION, 1998, 97 (11) :1029-1036
[8]   COMPOSITION OF HUMAN LOW-DENSITY-LIPOPROTEIN - EFFECTS OF POSTPRANDIAL TRIGLYCERIDE-RICH LIPOPROTEINS, LIPOPROTEIN-LIPASE, HEPATIC LIPASE AND CHOLESTERYL ESTER TRANSFER PROTEIN [J].
KARPE, F ;
TORNVALL, P ;
OLIVECRONA, T ;
STEINER, G ;
CARLSON, LA ;
HAMSTEN, A .
ATHEROSCLEROSIS, 1993, 98 (01) :33-49
[9]  
LABELLE M, 1990, J LIPID RES, V31, P1577
[10]   More on atorvastatin and fibrinogen [J].
Otto, C ;
Schwandt, P .
ATHEROSCLEROSIS, 2000, 151 (02) :591-592